Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 22Other hematologic neoplasm 13Gastrointestinal 9Lymphoid 8Genitourinary 6Tumor-Agnostic 5Other solid neoplasm 5Head & Neck 5Gynecologic 5CNS 5Thoracic 4Plasma cell 4Dermatologic 4Sarcoma 3Other 2Myeloid 2Classical hematology 1

Conditions

Multiple Myeloma 4Renal Insufficiency 1Recurrence 1Peripheral Nervous System Diseases 1Neoplasms 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Tablets × Plasma cell × Clear all
NCT07025005 2025-11-04

VRd MM Fibrate

Tanta University

Phase 4 Recruiting
44 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Peripheral Nervous System Diseases

NCT04717700 2025-03-18

SABLe

Odense University Hospital

Phase 2 Active not recruiting
50 enrolled
Plasma cell

Multiple Myeloma

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Celgene

Phase 2 Completed
81 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡